Abstract
42297 Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have